BioAtla (BCAB) Receivables (2025 - 2026)
BioAtla's (BCAB) quarterly Receivables came in at $6.5 million in Q2 2026, up 109.68% quarter-over-quarter from $3.1 million in Q4 2025.
Powered by 
Analysis
BioAtla (BCAB) Receivables (2025 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Receivables for 2 consecutive years, with $6.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Receivables changed N/A year-over-year to $6.5 million; the trailing twelve-month figure through Jun 2026 stood at $6.5 million (changed N/A YoY), and the FY2025 full-year result was $3.1 million, changed N/A from the prior year.
- Receivables improved to $6.5 million in Q2 2026 per BCAB's latest filing, from $3.1 million in the prior quarter.
- Across five years, Receivables topped out at $6.5 million in Q2 2026 and bottomed at $3.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 6.50 Mn |